Health Kick Podcast: Filamon’s bold push against cancer and chronic disease

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim speaks with Professor Paul de Souza, medical oncologist and co-founder of private drug developer Filamon, which is advancing a pipeline of anti-inflammatory therapies for cancer and chronic disease.

The company’s lead compound, a cyclic peptide with early signs of tolerability, is headed into a Phase 1b/2a adaptive trial, targeting multiple late-stage solid tumours by disrupting the tumour microenvironment.

Filamon’s founders bring decades of clinical and research experience, with a long-standing collaboration underpinning its scientific approach.

And with a second fundraising round underway, the team is eyeing a future ASX listing.

Tune into the podcast to hear more about Filamon’s mission and what’s next.

This podcast was developed in collaboration with Filamon, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.